Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

COVID-19 complications

SARS-CoV-2 infection boosts inflammation in atherosclerotic plaques

Nature Cardiovascular Research volume 2, pages 966–967 (2023)Cite this article

Subjects

The incidence of acute cardiovascular events, including myocardial infarction and ischemic stroke, is increased in individuals with COVID-19. A study shows that SARS-CoV-2 can directly infect macrophages and foam cells in atherosclerotic plaques and contribute to plaque instability.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: SARS-CoV-2 infects coronary vessel lesions.

References

  1. Giacca, M. & Shah, A. M. Nat. Cardiovasc. Res. 1, 200–210 (2022).

    Article  Google Scholar 

  2. Katsoularis, I., Fonseca-Rodriguez, O., Farrington, P., Lindmark, K. & Fors Connolly, A. M. Lancet 398, 599–607 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Shi, S. et al. Eur. Heart J. 41, 2070–2079 (2020).

    Article  CAS  PubMed  Google Scholar 

  4. Shi, S. et al. JAMA Cardiol. 5, 802–810 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Lala, A. et al. J. Am. Coll. Cardiol. 76, 533–546 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Eberhardt, N. et al. Nat. Cardiovas. Res. https://doi.org/10.1038/s44161-023-00336-5 (2023).

    Article  Google Scholar 

  7. Bussani, R. et al. J. Pathol. 259, 254–263 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ackermann, M. et al. N. Engl. J. Med. 383, 120–128 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bussani, R. et al. EBioMedicine 61, 103104 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Braga, L. et al. Nature 594, 8–93 (2021).

    Article  Google Scholar 

  11. Cappelletto, A. et al. Front Cardiovasc. Med. 9, 1013262 (2022).

    Article  CAS  PubMed  Google Scholar 

  12. Lemke, G. Nat. Rev. Immunol. 19, 539–549 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Xie, Y., Xu, E., Bowe, B. & Al-Aly, Z. Nat. Med. 28, 583–590 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Zakeri, R. et al. EClinicalMedicine 28, 100574 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  15. Nafilyan, V. et al. Eur. J. Epidemiol. 36, 605–617 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Work in the Giacca laboratory is supported by the European Research Council (ERC) Advanced Grant 787971 ‘CuRE’; British Heart Foundation (BHF) program grant RG/19/11/34633; King’s College London BHF Centre of Research Excellence grant RE/18/2/34213; grants 825670 ‘CardioReGenix’ and 874764 ‘REANIMA’ from the European Commission Horizon 2020 program.

Author information

Authors and Affiliations

  1. School of Cardiovascular and Metabolic Medicine & Sciences, British Heart Foundation Centre of Research Excellence, King’s College London, London, UK

    Mauro Giacca

Authors
  1. Mauro Giacca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mauro Giacca.

Ethics declarations

Competing interests

M.G. is founder, consultant, member of the Board and equity holder in Forcefield Therapeutics, Heqet Therapeutics and Purespring Therapeutics.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Giacca, M. SARS-CoV-2 infection boosts inflammation in atherosclerotic plaques. Nat Cardiovasc Res 2, 966–967 (2023). https://doi.org/10.1038/s44161-023-00358-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s44161-023-00358-z

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing